Loading stock data…
TIL
$8.02-0.06 (-0.74%)
After Hours$8.02+0.00 (+0.00%)· Last close Jun 9
Instil Bio, Inc., a biopharmaceutical company, focuses on identifying and advancing therapeutic opportunities.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Instil Bio, Inc. in the Healthcare sector is trading at $8.02. Wall Street consensus targets $7.00 (1 analysts), implying a -12.7% move over the next 12 months. The stock is currently near its 52-week low of $5.67, remaining 35.2% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 5/100 signals elevated caution as multiple indicators diverge.
Ecosystem Influences
Sell-side targets imply -12.7% downside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$8.02
Potential Downside
0%
Whystock Fair Value$8.02
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Instil Bio, Inc., a biopharmaceutical company, focuses on identifying and advancing therapeutic opportunities. It seeks to in-license or acquire and develop additional novel therapeutic candidates in diseases with significant unmet medical need. Inst...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
-
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-42.80%
Volume
Today's trading volume
16,123
Recent News
CarMax Stock Down 47% This Past Year, But One Fund Is Betting $6 Million on a Turnaround
CarMax runs a nationwide network of used car stores and digital channels, offering multi-channel sales and financing to U.S. consumers.
Alumis Stock Has Rallied 250% This Past Year. One Fund Sold Its $5 Million Stake Last Quarter.
This clinical-stage biotech develops therapies targeting autoimmune and neuroinflammatory diseases with a focus on TYK2 inhibition.
Instil Bio, Inc. (NASDAQ:TIL) is definitely on the radar of institutional investors who own 36% of the company
NasdaqCM:TIL 1 Year Share Price vs Fair Value Explore Instil Bio's Fair Values from the Community and select yours Key...
Instil Bio, Inc. (TIL) Is Up 4.07% in One Week: What You Should Know
Does Instil Bio, Inc. (TIL) have what it takes to be a top stock pick for momentum investors? Let's find out.
Wall Street Analysts Think Instil Bio (TIL) Could Surge 246.68%: Read This Before Placing a Bet
The mean of analysts' price targets for Instil Bio (TIL) points to a 246.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.